<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902018000200192</article-id>
<article-id pub-id-type="doi">10.29262/ram.v65i2.2927</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Eficacia a largo plazo del omalizumab en pacientes con queratoconjuntivitis vernal resistente a tratamiento convencional]]></article-title>
<article-title xml:lang="en"><![CDATA[Long-term efficacy of omalizumab in patients with conventional treatment-resistant vernal keratoconjunctivitis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santamaría]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Antioquia Grupo de Alergología Clínica y Experimental ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación para el Desarrollo de las Ciencias Médicas y Biológicas  ]]></institution>
<addr-line><![CDATA[Cartagena de Indias ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<volume>65</volume>
<numero>2</numero>
<fpage>192</fpage>
<lpage>196</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902018000200192&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902018000200192&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902018000200192&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Antecedentes:  En la queratoconjuntivitis vernal, los tratamientos tradicionales a veces son insuficientes para controlar los síntomas; los resultados con omalizumab son prometedores en los casos resistentes.  Reporte de caso:  Adolescente de 15 años con queratoconjuntivitis vernal quien había recibido múltiples tratamientos oftálmicos, inmunoterapia y esteroides sistémicos sin respuesta clínica. Acudió a un servicio de inmunología clínica y alergia donde se comenzó tratamiento con 225 mg de omalizumab cada dos semanas. Después de seis meses mostró disminución del prurito y de la fotofobia; dos años más tarde habían desaparecido las papilas y puntos de Horner-Trantas. La paciente permaneció sin síntomas, por lo que redujo el uso de medicamentos oftálmicos. En cuatro ocasiones suspendió la aplicación de omalizumab, sin embargo, los síntomas recurrían y reaparecían las papilas, que remitían al reiniciar el fármaco.  Conclusión:  En la paciente descrita existió relación temporal entre la administración de omalizumab y el control de los síntomas oculares, con evidencia de recaída después de la interrupción.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Background:  In vernal keratoconjunctivitis, traditional treatments are sometimes insufficient for symptom control; the results with omalizumab are promising in resistant cases.  Case report:  15-year-old female adolescent with vernal keratoconjunctivitis who had received multiple ophthalmic treatments, immunotherapy and systemic steroids with no clinical response. She attended a clinical immunology and allergy department where she was started on omalizumab 225 mg every 2 weeks. After 6 months, she showed a decrease in pruritus and photophobia; two years later, both papillae and Horner-Trantas dots had disappeared. She remained symptom-free, and the use of ophthalmic drugs was therefore reduced. The patient missed omalizumab application on 4 occasions; however, symptoms recurred, and the papillae reappeared, but remitted upon drug re-initiation.  Conclusion:  There is a temporal relationship between omalizumab administration and ocular symptom control, with evidence of relapse upon discontinuation.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Alergia]]></kwd>
<kwd lng="es"><![CDATA[Atopia]]></kwd>
<kwd lng="es"><![CDATA[Conjuntivitis]]></kwd>
<kwd lng="es"><![CDATA[Queratoconjuntivitis vernal]]></kwd>
<kwd lng="es"><![CDATA[Omalizumab]]></kwd>
<kwd lng="en"><![CDATA[Allergy]]></kwd>
<kwd lng="en"><![CDATA[Atopy]]></kwd>
<kwd lng="en"><![CDATA[Conjunctivitis]]></kwd>
<kwd lng="en"><![CDATA[Vernal keratoconjunctivitis]]></kwd>
<kwd lng="en"><![CDATA[Omalizumab]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Reina]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Espinoza]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cardona]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Queratoconjuntivitis vernal refractaria ¿es el tacrolimus una opción terapéutica? Estudio prospectivo]]></article-title>
<source><![CDATA[Alerg Asma Inmunol Pediatr]]></source>
<year>2012</year>
<volume>21</volume>
<page-range>5-12</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Piedrahita]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Caraballo]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Girado]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Cardona-Villa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad de la inmunoterapia con alergenos en pacientes con queratoconjuntivitis vernal]]></article-title>
<source><![CDATA[Rev Alerg Mex]]></source>
<year>2013</year>
<volume>60</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El-Qutob]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Off-label uses of omalizumab]]></article-title>
<source><![CDATA[Clin Rev Allergy Immunol]]></source>
<year>2016</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>84-96</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cardona]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab An option in vernal keratoconjunctivitis?]]></article-title>
<source><![CDATA[Allergol Immunopathol (Madr)]]></source>
<year>2012</year>
<volume>40</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>319-20</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<name>
<surname><![CDATA[Sheppard]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab A future innovation for treatment of severe ocular allergy?]]></article-title>
<source><![CDATA[Expert Opin Biol Ther]]></source>
<year>2005</year>
<volume>5</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1603-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Amat]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gabison]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Saf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cochereau]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Just]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab in severe refractory vernal keratoconjunctivitis in children: case series and review of the literature]]></article-title>
<source><![CDATA[Ophthalmol Ther]]></source>
<year>2016</year>
<volume>3</volume>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Klerk]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Arkwright]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Biswas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab]]></article-title>
<source><![CDATA[J AAPOS]]></source>
<year>2013</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>305-6</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Occasi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zicari]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Petrarca]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nebbioso]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Salvatori]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Duse]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vernal keratoconjunctivitis and immune-mediated diseases One unique way to symptom control?]]></article-title>
<source><![CDATA[Pediatr Allergy Immunol]]></source>
<year>2015</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>289-91</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heffler]]></surname>
<given-names><![CDATA[Enrico]]></given-names>
</name>
<name>
<surname><![CDATA[Picardi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Liuzzo]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Pistorio]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Crimi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab treatment of vernal keratoconjunctivitis]]></article-title>
<source><![CDATA[JAMA Ophthalmol]]></source>
<year>2016</year>
<volume>1</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>2-4</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
